|Clinical Trial Title||Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma|
|Trial Status||Closed to Enrollment|
|Trial Type||Pediatric Cancer (Oncology)|
|Specific Condition||Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Unclassified soft tissue sarcoma, and Other soft tissue neoplasms (excluding benign tumors).|
|Description||A COG soft tissue sarcoma diagnosis, biology and banking protocol.
Patients enrolled on D9902 fall into one of three groups:
Category 1: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review stratum of D9902.
Category 2: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review and Biology/Banking strata of D9902.
Category 3: Patients NOT planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can only enroll on the Biology/Banking stratum of D9902. Pathology Central Review will not be performed for clinical purposes or to meet any of the research objectives, except to establish the bank. The enrolling investigator/institution will not receive a report back from COG regarding the submitted sample.
|Eligibility Criteria||Age: patients must be < 50 years of age at the time of enrollment
Patients must have one of the following histologically-confirmed diagnoses: Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), unclassified soft tissue sarcoma that is too undifferentiated to be placed in a specific pathologic category in the WHO classification, and other soft tissue neoplasms, excluding benign tumors
Patients with malignant rhabdoid tumor, Ewing sarcoma/PNET, or ostogenic sarcoma of bone are NOT eligible for enrollment on D9902
Study status is:
Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
|Principal Investigator||Janice Olson, MD|
|Contact Name||Children's Cancer and Blood Disorders Program|
|Contact Phone||(503) 276-9300|